2[2]Fearon ER,Hamilton SR,Vogelstein B.Clonal analysis of human colorectal tumors.Science 1987; 238:193-197
3[3]Kallioniemi OP,Wagner U,Kononen J,Sauter G.Tissue microarray technology for high-throughput molecular profiling of cancer.Hum Mol Genet 2001; 10:657-662
4[4]Serrano R,Gómez M,Farre X,Méndez M,De La Haba J,Morales R,Sanchez L,Barneto I,Aranda E.Tissue microarrays (TMAS) in colorectal cancer:Study of clinical and molecular markers.ASCO Meeting Abstracts 2004; 22:9665
5[5]Chung DC.The genetic basis of colorectal cancer:insights into critical pathways of tumorigenesis.Gastroenterology 2000; 119:854-865
6[6]Hao X,Tomlinson I,Ilyas M,Palazzo JP,Talbot IC.Reciprocity between membranous and nuclear expression of beta-catenin in colorectal tumours.Virchows Arch 1997; 431:167-172
7[7]He TC,Sparks AB,Rago C,Hermeking H,Zawel L,da Costa LT,Morin PJ,Vogelstein B,Kinzler KW.Identification of c-MYC as a target of the APC pathway.Science 1998; 281:1509-1512
8[8]Kim JY,Lim SJ,Park K.Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays.Appl Immunohistochem Mol Morphol2004; 12:67-70
9[9]Messinetti S,Giacomelli L,Fabrizio G,Giarnieri E,Gabatel R,Manno A,Feroci D,Guerriero G,Masci E,Vecchione A.CD44v6 and Nm23-H1 protein expression related to clinicopathological parameters in colorectal cancer.Ann Ital Chir 2003; 74:45-51
10[10]Zhou XP,Loukola A,Salovaara R,Nystrom-Lahti M,Peltom(a)ki P,de la Chapelle A,Aaltonen LA,Eng C.PTEN mutational spectra,expression levels,and subcellular localization in microsatellite stable and unstable colorectal cancers.Am J Pathol 2002; 161:439-447
4Prabhu V, Shivani A. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evalua- tion of prognostic scoring in adults[J]. Ann Med Health Sci Res, 2014, 4(1):22-29.
5Hongo M, Kimpara T, Moriyama S, et al. Effect of rabepra- zole, a novel proton pump inhibitor on intragastric pH in healthy volunteers[J]. Tohoku J Exp Med, 1998, 186(1):43- 50.
6Wang Y, Waldron TR, Dhaka A, et al. The Ras effector RIN1 derectly competes with RAF and is regulated by 14-3-3 proteins [J]. Mol Cell Biol, 2002, 22(3): 916-926.
7Bliss JM, Venkatesh B, ColicelliJ. The RIIq family of Ras effectors[J]. Methods Enzymol, 2006, 407: 335-344.
8Hu H, Bliss JM, Wang Y~ et al. RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration[J]. Curr Biol, 2005, 15(9): 815-823.
9Cao X, Tanis KOa Koleske AJ, et al. Enhancemnt ofABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms [J]. J Biol Chem, 2008, 283 (46): 31401-31407.
10Younos IH, Dafferner AJ, Gulen D, et al. Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking [J]. Int Immunopharmacol, 2012, 13(3): 245-256.
